Bichen Medical Completes RMB 300 Million Series C Financing to Advance Integrated Clinical Mass Spectrometry Solutions

VCBeat has learned that on March 3, Zhejiang BIOZON Medical Technology Co., Ltd. (hereinafter referred to as “BIOZON”), a clinical mass spectrometry testing company, announced the completion of its C-round financing amounting to RMB 300 million. The round was led by CPE, with participation from Huagai Capital and Sherpa Investments, while China Renaissance served as the exclusive financial advisor. The proceeds will be used to increase R&D investment, continuously enhance its core technology product portfolio and hardware development, further accelerate the deployment and comprehensive coverage of its products in medical institutions, and speed up the layout of a precision medicine ecosystem. This financing round set a new record for the largest single fundraising amount in China’s clinical mass spectrometry field, marking a significant milestone.

To date, BIOZON has completed four rounds of financing, garnering interest from multiple investment firms, including Ningbo Shiyi, Puhua Capital, Hechuang Capital, Fortune Capital, Shanlan Capital, Haida Capital, Shengding Investment, and Zhongnuo Synergy.

BIOZON is the first innovative biotechnology company in China to be driven by clinical needs, integrating multi-platform technologies centered on mass spectrometry and multi-omics data to provide precise diagnosis and treatment solutions. The company focusesProvide an integrated solution for clinical mass spectrometry testing, integrating instruments and equipment, reagent products, testing services, and academic systems to build a complete clinical diagnosis and treatment ecosystem., The core team has been deeply engaged in the clinical mass spectrometry testing industry for many years, possessing profound clinical and technical backgrounds. With extensive experience in product development, operational management, and marketing, the team is capable of accurately identifying unmet clinical needs and fully leveraging the advantages of mass spectrometry technology in clinical practice.

With a clear strategic positioning and strong execution capabilities, BIOZON has independently developed solutions in the four major fields of maternal and child health, mental health, endocrinology, and oncology.Over 300 test items, nearly 70 in vitro diagnostic (IVD) kits, and five models of mass spectrometry instruments and related sample preparation equipment.Meanwhile, it has applied for and obtained more than 20 national invention patents. To date, the company’s business has expanded to over 20 provinces, municipalities, and autonomous regions across China,Partnered with nearly 1,000 medical institutions, providing integrated clinical mass spectrometry platform solutions to over 100 Grade IIIA hospitals in China.

The clinical mass spectrometry testing sector is regarded as the next trillion-yuan blue-ocean market. Mass spectrometry technology offers unique advantages, including high sensitivity, excellent specificity, and the ability to perform multiplexed parallel detection of multiple analytes. It serves both as a complement to and an extension of existing diagnostic technologies, enhancing the precision of current laboratory tests and enabling the measurement of biomarkers inaccessible to other methods. This capability better informs clinical diagnosis and provides patients with more accurate test results.

Mass spectrometry testing is one of the most important platforms for precision diagnostics in the era of precision medicine. It is poised to become the next major comprehensive testing platform, following biochemical, immunological, and molecular diagnostics, with significant prospects for future development. Next,BIOZON will center on mass spectrometry technology, integrate multi-omics and multi-platform big data analytics, and continuously advance product research, development, and commercialization, positioning itself as a leader in the precision medicine industry.

Dr. Gao Qiang, Founder and CEO of the company, stated that precision medicine and personalized therapy represent the future direction of medical development. The foundation of precision medicine lies in precise diagnosis, and the emerging trend is to address complex diseases from a systems biology perspective by integrating molecular, proteomic, and metabolomic data. BIOZON will center its efforts on mass spectrometry, integrate multi-platform multi-omics data for product development, continuously launch solutions that meet clinical needs, expand its service network coverage, and consistently enhance the quality of its products and services as well as customer experience. Committed to becoming a leader in the precision medicine industry, BIOZON strives to fulfill its corporate mission of promoting healthier lives.

Cao Xia, Project Leader at CPE, stated, “Clinical mass spectrometry testing is characterized by high resolution, high sensitivity, and high specificity. It is one of the most important diagnostic technology platforms in the era of precision medicine and a key focus area for CPE in the field of precision healthcare. BIOZON is an outstanding domestic company specializing in mass spectrometry testing. Adhering to a clinical-need-centric approach, it has innovatively developed a variety of testing methods required for clinical practice and provides integrated clinical solutions. This has helped narrow the gap between China and the United States in testing technologies, offering more precise and effective evidence for clinical diagnosis and treatment. CPE is highly optimistic about BIOZON’s development in the field of mass spectrometry and will continue to support its innovation driven by clinical needs, thereby contributing to the advancement of precision diagnosis and treatment in China.”

Zeng Zhiqiang, Managing Partner of Huagai Capital’s Healthcare Fund, stated, “Huagai Capital is highly optimistic about the clinical application of mass spectrometry testing. Leveraging its methodological advantages in high sensitivity and high accuracy, mass spectrometry is poised to play a significant role in diagnosing diseases that are undetectable by conventional methods. Furthermore, mass spectrometry will demonstrate its strengths in multi-omics testing, fostering innovative diagnostic applications through integrated data analysis. The management team of BIOZON has accumulated profound expertise and deep insights in the field of mass spectrometry, with its products and services receiving high recognition from experts. Huagai Capital is honored to participate in this round of financing. We will facilitate the integration of medical resources for the company, supporting it in becoming a leader in the mass spectrometry sector and continuously creating value for society.”

Xing Cheng, Partner at Sherpa Investment Management, stated, “Clinical mass spectrometry is a field with immense growth potential that is also fraught with challenges. Through years of dedicated efforts, BIOZON has emerged as the leading enterprise in this sector. The company’s robust talent framework, strategic layout across service, product, and distribution channels, along with its well-defined strategy and development path, have laid a solid foundation for BIOZON’s long-term growth. We are honored to partner with the company and witness the sustained development of this field.”

Zhou Xiang, Head of the Financial Advisory Division at China Renaissance, stated, “Precision medicine is the central theme of the healthcare industry. We are firmly optimistic about clinical mass spectrometry as a platform technology for precision diagnostics, given its irreplaceable clinical value in advancing precision medicine. The BIOZON team boasts profound industry expertise and deep clinical insights, consistently focusing on critical clinical needs to develop innovative clinical applications and build a comprehensive diagnostic and therapeutic ecosystem, thereby supporting the development of precision medicine in China. We are honored to serve as the exclusive financial advisor for the company’s current financing round and believe that, bolstered by this funding, the company will accelerate its growth and continue to lead the robust development of the clinical mass spectrometry sector.”